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Abstract
Background: Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA)
with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing
treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare
the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA
bacteremia.
Methods: Patients with MSSA bacteremia recruited from a tertiary referral hospital were enrolled in this retrospective
cohort study. Demographic characteristics, laboratory data, and clinical outcome of the treatment were compared
between a group receiving nafcillin and a group receiving glycopeptides.
Results: A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a
higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%,
p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and
bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.
022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7
vs. 20.6%, p = 0.013).
Conclusion: In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with
glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive
therapy for MSSA bacteremia.
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Background
Staphylococcus aureus (S. aureus) is one of the most
common causes of community-acquired and healthcare-
associated bacteremia [1]. The incidence of infection
induced by methicillin-resistant S. aureus (MRSA) has
been increasing [2, 3]. In Korea, a recent nationwide sur-
vey reported a methicillin-resistance rate of S. aureus of
66% in the general population [4]. Therefore, many
clinicians therefore use glycopeptides such as vanco-
mycin as their first choice of antibiotics for empirical
treatment of S. aureus bacteremia to cover both MRSA
and methicillin-susceptible S. aureus (MSSA) before
confirming antibiotic susceptibility. However, some
physicians continue to use the glycopeptide without
changing to β-lactam antibiotics after confirmation of
MSSA bacteremia.
Many studies comparing the efficacy of β-lactam
antibiotics, including antistaphylococcal penicillin and
glycopeptides, as empirical therapy for MSSA bacteremia
have been conducted, and β-lactam agents have been
found to be superior in the treatment of MSSA
bacteremia compared with glycopeptides in these studies
[5–8]. Wong et al. reported that empiric β-lactams was
associated with earlier clearance of MSSA bacteremia
compared to vancomycin (70.7 vs. 97.1 h, p = 0.007) [5].
Additionally, Schweizer et al. reported that β-lactams
showed protective effectiveness against mortality com-
pared to vancomycin in patients with MSSA bacteremia
(adjusted hazard ratio, 0.21; 95% CI, 0.09–0.47) [9].
However, there were few studies comparing glycopep-
tides and antistaphylococcal penicillin such as nafcillin
alone as a treatment for MSSA bacteremia. This study
aimed to compare the efficacy of nafcillin, an antistaphy-
lococcal antibiotic, with that of glycopeptides including
vancomycin and teicoplanin, as definitive therapy for pa-
tients with MSSA bacteremia.
Methods
Study population
We consecutively included patients with confirmed S.
aureus bacteremia recruited from a single tertiary refer-
ral hospital from April 2012 to June 2016 in this retro-
spective cohort study. The referral hospital is a 2400-bed
institution affiliated with Yonsei University College of
Medicine in Seoul, South Korea. All participants were
aged 18 years or older. Patients receiving a definitive
therapy with nafcillin, vancomycin, or teicoplanin were
included in this study. Patients who had MRSA infections
or received treatment with other single antibiotics such as
first generation cephalosporin, quinolone, or β-lactam/β-
lactamase inhibitor combinations were excluded. Patients
with bacteremia caused by other pathogens and those
who died before the causative organism could be con-
firmed were also excluded. Participants were divided into
the “nafcillin group” and the “glycopeptide group”. The
study was approved by the institutional review board of
the Yonsei University Health System Clinical Trial Center
(#4–2017-0070).
Data collection
Baseline characteristics such as age, sex, and preexisting
comorbidities including cardiovascular disease, cerebral
vascular accidents, dementia, lung disease, autoimmune
disease, peptic ulcer disease, chronic kidney disease, dia-
betes, liver disease, and malignancy were recorded. Data
on the source of the bacteremia and on whether the pa-
tient’s infection was community-acquired or healthcare-
associated were collected. According to the source of
bacteremia, we subdivided the patient sample into groups
with catheter-related infection, pneumonia, urinary
tract infection, skin and soft tissue infection, bone
and joint infection, intra-abdominal infection, and pri-
mary bacteremia.
Laboratory tests were undertaken within the first 24 h
after a culture was drawn. Tests included white blood
cell (WBC) count, platelet counts, creatinine levels, esti-
mated glomerular filtration rate, total bilirubin levels,
prothrombin time (international normalized ratio), and
C-reactive protein (CRP) levels. As the index of disease
severity, the Pitt bacteremia score was calculated [10].
To assess the clinical outcome, we analyzed the patient
data with respect to hospitalization duration, whether or
not participants received intensive care unit (ICU) care,
duration of stay at the ICU, persistent bacteremia, and
all-cause 28-day mortality. The results of an antimicro-
bial susceptibility test, performed in accordance with the
Clinical & Laboratory Standards Institute guidelines,
were obtained from the patients’ medical records [11].
Definition
If bacteremia was identified within 48 h of admission
and the participant had no history of admission to
healthcare institutions within 3 months prior to admis-
sion, their infection was assumed to be community-
acquired. If bacteremia was identified after 48 h or if the
participant had an admission history within 3 months
prior to admission, their infection was assumed to be
healthcare-associated. Definitive therapy was defined as
initiated or continued antibiotic treatment after identifi-
cation of the pathogen in blood culture and in an anti-
biotic susceptibility test [12]. The source of infection,
such as catheter-related infection, pneumonia, urinary
tract infection, skin and soft tissue infection, bone and
joint infection, and intra-abdominal infection was defined
based on the criteria laid out by the Centers for Disease
Control and Prevention, USA [13]. WBC counts equal to
or above 10,000/mm3 are considered leukocytosis.
Leukopenia is defined as WBC counts under 4000/mm3.
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Thrombocytopenia is defined as platelet counts less
than 150 × 103/mm3. Persistent bacteremia is defined as
the isolation of S. aureus in blood cultures obtained
from peripheral veins for more than 7 consecutive days
despite adequate antibiotic administration for more
than 5 days. Mortality involving at least one of the
following are defined as bacteremia-related mortality:
(i) blood cultures were positive at the time of death; (ii)
death occurred before the resolution of bacteremia; (iii)
death occurred during hospitalization without other
specific cause except bacteremia [14].
Statistical analysis
Continuous variables were expressed as mean ± stand-
ard deviation or median (interquartile range) and
compared using the Student’s t-test if the variables
followed a normal distribution. Continuous variables
with skewed distribution were compared using the
Mann-Whitney U-test. The chi-squared test was used
when all the categorical variables included in the
analysis were 5 or more. If any of the categorical
variables included in the analysis has a value of less
than 5, it was analyzed using Fisher’s exact test. To
compare survival rates between the nafcillin group
and the glycopeptide group, a Kaplan-Meier survival
curve was used. The Cox regression model was used
to analyze prognostic factors for mortality. All statis-
tical analyses were performed using the Statistical
Package for the Social Sciences 18.0 software (SPSS
Inc., Chicago, IL, USA). P values under 0.05 were
considered statistically significant.
Results
A total of 695 patients with S. aureus bacteremia were
identified for screening. Three hundred and fifty patients
with MRSA infection were excluded, and 35 patients who
died before antimicrobial susceptibility was confirmed
were also excluded. Additionally, 30 patients with coinfec-
tions with other bacteria and 92 patients treated with
other antibiotics were excluded. Among the remaining
280 patients, 188 patients who underwent treatment with
nafcillin, vancomycin, or teicoplanin were finally enrolled
in this study. Ninety-one patients received nafcillin, and
97 patients received glycopeptides (vancomycin or teico-
planin) as definitive therapy (Fig. 1).
The mean age of the study participants was 62.37 ±
15.14 years, and 69% (n = 129) of all patients were male.
With regard to underlying diseases, the patients in the
glycopeptide group had a significantly higher rate of ma-
lignancy than the patients in the nafcillin group (28.6 vs.
60.8%, p < 0.001). There was no significant difference
with regard to other comorbidities. Additionally, the pa-
tients in the glycopeptide group had a higher proportion
of healthcare-associated infections (47.3 vs. 72.2%, p <
0.001). The most common infection source was skin and
soft tissue infection (23.1%), followed by catheter-related
infection and bone and joint infection (11.8%, respect-
ively). Skin and soft tissue infections (30.0 vs. 16.7%, p =
0.037) and bone and joint infections were common in
the nafcillin group. Laboratory tests showed that the me-
dian CRP level was significantly higher in the nafcillin
group than in the glycopeptide group (139.60 vs.
107.61 mg/dL, p = 0.022). There was no significant dif-
ference in other laboratory tests (Table 1).
Fig. 1 Study flow diagram
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With regard to the antimicrobial susceptibility of identi-
fied MSSA, we found a relatively high resistance rate to
penicillin G (85.1%), erythromycin (17.1%), and clindamy-
cin (15.4%). Resistance to other antibiotics was relatively
low. There was no significant difference in resistance rates
between the two patient groups except for clindamycin
(8.8 vs. 21.6%, p = 0.016) (Additional file 1).
The median hospitalization period and the mean
duration of stay at the ICU of all participants were 22.0
(14.0–39.5) days and 5.03 ± 14.10 days, respectively. The
rate of persistent bacteremia was 9.6%. There was no
difference between the two groups in terms of
hospitalization period (22.0 vs. 22.0 days, p = 0.764).
There were no significant differences in the duration of
Table 1 Comparison of baseline characteristics and laboratory test results between the patient groups treated with either nafcillin or
glycopeptides
Characteristics All patients
(n = 188)
Nafcillin group
(n = 91)
Glycopeptide group
(n = 97)
P value
Age, years, mean ± SD 62.37 ± 15.14 64.38 ± 14.53 60.46 ± 15.54 0.076 a
Male, (%) 129 (69.0) 61 (67.0) 68 (70.8) 0.636 b
Underlying comorbidities, yes (%)
Cardiovascular disease 55 (29.3) 29 (31.9) 26 (26.8) 0.522 b
Cerebral vascular accident 19 (10.1) 12 (13.2) 7 (7.2) 0.227 b
Dementia 5 (2.7) 1 (1.1) 4 (4.1) 0.370 c
Lung disease 14 (7.4) 8 (8.8) 6 (6.2) 0.584 b
Autoimmune disease 10 (5.3) 4 (4.4) 6 (6.2) 0.749 c
Peptic ulcer disease 10 (5.3) 6 (6.6) 4 (4.1) 0.527 c
Chronic kidney disease 39 (20.7) 23 (25.3) 16 (16.5) 0.153 b
Diabetes 62 (33.0) 35 (38.5) 27 (27.8) 0.162 b
Liver disease 23 (12.2) 8 (8.8) 15 (15.5) 0.187 b
Malignancy 85 (45.2) 26 (28.6) 59 (60.8) <0.001 b
CA vs. HCA, HCA (%) 113 (60.1) 43 (47.3) 70 (72.2) <0.001 b
Pit bacteremia score, mean ± SD 1.56 ± 2.55 1.42 ± 2.39 1.69 ± 2.71 0.465 a
Infection focus, yes (%)
Catheter-related infection 22 (11.8) 12 (13.3) 10 (10.4) 0.651 b
Pneumonia 8 (4.3) 1 (1.1) 7 (7.3) 0.066 c
Urinary tract infection 7 (3.8) 9 (6.7) 1 (1.0) 0.058 c
Skin and Soft tissue infection 43 (23.1) 27 (30.0) 16 (16.7) 0.037 b
Bone and Joint infection 22 (11.8) 16 (17.8) 6 (6.3) 0.022 b
Intra-abdominal infection 13 (7.0) 3 (3.3) 10 (10.4) 0.083 c
Primary bacteremia 74 (39.8) 27 (30.0) 47 (49.0) 0.011 b
Laboratory tests
WBC, /mm3, median (IQR) 10,150 (7,635–14,770) 10,450 (8,120–15,280) 9,860 (5,485–14,615) 0.064 d
Leukocytosis or Leukopenia, yes (%) 116 (61.7) 50 (54.9) 66 (68.0) 0.073 b
Platelet counts, ×103/mm3, median (IQR) 169 (95–250) 182 (115–257) 164 (83–250) 0.190 d
Thrombocytopenia, yes (%) 82 (43.6) 36 (39.6) 46 (47.4) 0.305 b
eGFR, mL/min/mm3, mean ± SD 62.88 ± 28.60 62.38 ± 28.27 63.35 ± 29.06 0.818 a
Total bilirubin, mg/dL, median (IQR) 0.8 (0.5–1.4) 0.8 (0.5–1.3) 0.8 (0.5–1.4) 0.452 d
Prothrombin time (INR), median (IQR) 1.12 (1.01–1.29) 1.13 (1.02–1.28) 1.11 (1.01–1.32) 0.895 d
CRP, mg/dL, median (IQR) 121.01 (56.34–200.85) 139.60 (79.68–219.00) 107.61 (42.19–192.90) 0.022 d
Abbreviations: SD standard deviation, CA community-acquired, HCA healthcare-associated, WBC white blood cell, IQR interquartile range, eGFR estimated glomeru-
lar filtration rate, INR international normalized ratio, CRP C-reactive protein
aStudent’s t-test
bPearson’s χ-test
cFisher’s exact test
dMann-Whitney U-test, median (interquartile range)
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ICU stay (3.71 vs. 6.26 days, p = 0.217) and in the ratio
of persistent bacteremia (12.2 vs. 7.2%, p = 0.323) be-
tween the two patient groups. (Table 2, Fig. 2). There
was a significant difference between the two patient
groups in all-cause 28-day mortality (7.7 vs. 20.6%, p =
0.013) and bacteremia-related 28-day mortality (4.4 vs.
14.4%, p = 0.025). Additionally, the Cox regression ana-
lysis showed that the use of glycopeptides was the sig-
nificant prognostic factor for mortality when adjusting
for malignancy, healthcare-associated infection, and CRP
(Hazard ratio, 2.615; 95% CI, 1.105–6.186, p = 0.029)
(Additional file 2).
Discussion
S. aureus bacteremia is a very severe clinical condition
that clinicians often experience. Since the infection rate
caused by MRSA is increasing, many clinicians use the
glycopeptide empirically. However, despite of confirming
MSSA bacteremia via bacterial culture, it is not uncom-
mon to maintain glycopeptide as definitive therapy for
the reason that severe comorbidities and disease severity.
There have been many studies related to the choice of a
definitive therapeutic agent for MSSA bacteremia, but
no study had compared prognosis with glycopeptide
with nafcillin alone, an antistaphylococcal agent. In our
current study, we found that the 28-day mortality rate
was significantly lower in a group of patients with MSSA
bacteremia receiving definitive therapy with nafcillin
compared to a group receiving treatment with. This
finding suggests that nafcillin should be considered as
the first choice for definitive antimicrobial therapy in
MSSA bacteremia.
Our finding of higher mortality in the vancomycin
group is in accordance with findings from several recent
studies. Mcdanel et al. reported a higher mortality rate
in patients who received vancomycin monotherapy com-
pared with patients who received β-lactam monotherapy,
as definitive therapy for MSSA bacteremia, after adjust-
ment for confounding factors such as severity of illness,
comorbidities, age, and others [7]. Kim et al. reported
higher mortality in patients who were treated with
vancomycin for MSSA bacteremia compared with pa-
tients receiving β-lactam agents [6].
Some explanations for the relative inferiority of vanco-
mycin in the treatment of MSSA have been proposed
[15]. Generally, β-lactam agents are classified as bacteri-
cidal to MSSA, whereas the bactericidal effect of vanco-
mycin is lower than that of β-lactam agents [15, 16].
Furthermore, vancomycin has a relatively narrow thera-
peutic range as compared to β-lactam agents, pharmaco-
logically [15]. Additionally, because teicoplanin is a
bacteriostatic agent with similar efficacy as vancomycin,
teicoplanin also poses problems that is smilar with
vancomycin in the treatment of MSSA [17].
In this study, the prevalence of malignancy and the
proportion of healthcare-associated infections were
higher in the glycopeptide group than in the nafcillin
group. In addition, skin and soft tissue infection as well
as bone and joint infection were more common in the
nafcillin group than in the glycopeptide group. However,
the use of glycopeptides was found to be the significant
prognostic factor for mortality when adjusting for these
variables. Thus, despite several confounding variables,
the choice of antibiotics, in this case nafcillin versus gly-
copeptides, in the treatment of MSSA bacteremia is an
important factor affecting patient mortality.
On the other hand, we found no significant difference
in persistent bacteremia in this study. Kim et al. reported
that there was no statistical difference in eradication of
infection foci between a β-lactam treatment group and a
vancomycin treatment group in patients with MSSA
bacteremia [6]. However, Wong el al. reported a signifi-
cant difference in the frequency of prolonged bacteremia
between a β-lactam treatment group and a vancomycin
treatment group [5]. Furthermore, Park et al. reported
significant differences in bacteremia duration between a
β-lactam treatment group, a vancomycin treatment
group, and a combination treatment group [18].
This study has several limitations. First, this is a retro-
spective cohort study and it is thus subject to selection
bias. Second, all data were collected from a single center,
so that generalization of these results to other institutions
Table 2 Clinical outcome of the different treatments
Characteristics All patients
(n = 188)
Nafcillin group
(n = 91)
Glycopeptide group
(n = 97)
P value
Hospitalization period, days, median (IQR) 22.0 (14.0–39.5) 22.0 (12.0–41.0) 22.0 (15.0–36.0) 0.764c
ICU stay, days, mean ± SD 5.03 ± 14.10 3.71 ± 12.47 6.26 ± 15.44 0.217a
Persistent bacteremia, (%) 18 (9.6) 11 (12.2) 7 (7.2) 0.323b
All-cause 28-day mortality, yes (%) 27 (14.4) 7 (7.7) 20 (20.6) 0.013b
Abbreviations: IQR interquartile range, ICU intensive care unit, SD standard deviation
aStudent’s t-test
bPearson’s χ-test
cMann-Whitney U-test, median (interquartile range)
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might be questionable. Additional prospective studies with
more selective and larger populations involving multiple
centers are necessary.
Conclusion
In conclusion, we find that all-cause 28-day mortality in
MSSA bacteremia is higher in patients receiving glyco-
peptides as definitive therapy compared to patients
receiving nafcillin. Therefore, the use of nafcillin should
be a first choice for definitive antimicrobial treatment in
MSSA bacteremia.
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